Advances in Molecular Therapeutics for HIV Co-Infections
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 March 2026 | Viewed by 2252
Special Issue Editors
Interests: mycobacterial diseases; tuberculosis; host immune responses; pathogenesis
Special Issues, Collections and Topics in MDPI journals
Interests: cytokine storm and type I interferon response in COVID-19 pathogenesis; mycobacterial infections; host directed therapy; tuberculosis; rabbit model; animal models; human pulmonary tb
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ever since human immunodeficiency virus (HIV) was first discovered in 1981 more than 40 million people have died due to acquired immunodeficiency syndrome (AIDS). Currently 38 million people are living with HIV infection. HIV compromises the body’s immune system, increasing the likelihood of contracting opportunistic infections.
AIDS patients often suffer or die due to tuberculosis (TB). HIV and TB are considered a syndemic, defined as “the convergence of two or more diseases that act synergistically to magnify the burden of disease”. Today, TB remains the leading infectious cause of death in people with HIV, who are 15–22 times more likely to contract TB than people without. Importantly, HIV has been linked to several outbreaks of TB globally, especially in sub-Saharan Africa.
Much is known about the syndemic relationship of HIV and TB, yet the specifics and mechanisms behind how these two diseases interact have not been entirely addressed. This review will explore how Mtb worsens HIV infection. The objective of this review is to provide an insight into the interaction between Mtb and HIV to help overcome the difficulties in co-treatment of HIV and TB.
The special issue therefore invites submissions on:
- Strategies to maintain the immune system in those with HIV infection tp prevent M. tb co-infection.
- Adjunctive therapies for HIV and M. tb co-infection.
- Novel therapies to prevent HIV infection and M. tb co-infection in HIV-infected individuals.
- Treatment that will maintain undetectable viral load to prevent co-infections with tuberculous and non-tuberculous mycobacterial infections.
- Efforts to prevent HIV from developing resistance to ART.
- Recent developments in understanding the host immune responses against HIV and M. tb/M. avium co-infections.
- Current breakthroughs in the understanding of M. tb pathogenesis in the context of HIV infection.
Prof. Dr. Vishwanath Venketaraman
Dr. Selvakumar Subbian
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV co-infections
- molecular therapeutics
- Mtb
- ART
- immune responses
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
